Ticagrelor Tablet Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 90 mg, 60 mg

Reference Brands: Brilinta(US & EU)

Category: Blood Disorder

Ticagrelor inhibits the P2Y12 receptor on platelets, preventing ADP-mediated activation and aggregation. It rapidly reduces clot formation, lowering the risk of heart attack and stroke in acute coronary syndrome. Benefits include fast action, reversible platelet inhibition, reduced cardiovascular events, and oral administration without the need for routine blood monitoring. Ticagrelor tablet is available in Tablet and strengths such as 90 mg, 60 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Ticagrelor tablet is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Ticagrelor tablet can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Ticagrelor, marketed as Brilinta, is approved in both the US by the FDA and in the EU via EMA for acute coronary syndrome and other cardiovascular indications. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing details, and pharmacovigilance plans. In the US, FDA review involves detailed submission of clinical trial results, while in the EU, EMA approval follows strict regional guidelines. For guidance on dossier preparation, regulatory pathways, and successful market entry strategies, visit PharmaTradz. Ensuring compliance with regional regulations is essential for the safe and effective commercialization of ticagrelor worldwide.